Poseida Therapeutics Target of Unusually High Options Trading (NASDAQ:PSTX)

Poseida Therapeutics, Inc. (NASDAQ:PSTX) saw unusually large options trading on Tuesday. Traders purchased 5,174 put options on the stock. This represents an increase of 3,372% compared to the average volume of 149 put options.

Institutional Investors Weigh In On Poseida Therapeutics

Several institutional investors have recently made changes to their positions in the company. Marshall Wace LLP bought a new position in shares of Poseida Therapeutics during the 2nd quarter worth about $31,000. Bayesian Capital Management LP acquired a new position in Poseida Therapeutics during the 1st quarter worth $33,000. Rothschild Investment LLC bought a new stake in Poseida Therapeutics during the 2nd quarter worth about $35,000. Principal Financial Group Inc. bought a new position in shares of Poseida Therapeutics in the 2nd quarter valued at about $35,000. Finally, Virtu Financial LLC acquired a new stake in Poseida Therapeutics during the 3rd quarter worth $37,000. 46.87% of the stock is currently owned by institutional investors and hedge funds.

Poseida Therapeutics Price Performance

Shares of PSTX traded up $6.52 during mid-day trading on Tuesday, hitting $9.38. The company’s stock had a trading volume of 21,172,146 shares, compared to its average volume of 643,383. Poseida Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $9.38. The stock has a market capitalization of $914.17 million, a price-to-earnings ratio of -4.54 and a beta of 0.54. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 3.20. The firm has a 50-day moving average price of $2.78 and a 200 day moving average price of $2.92.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and set a $9.00 price objective (down previously from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.